Phio Pharmaceuticals Corp. PHIO
0.84 USD +0.04 (+4.82%)
At closeNov 9, 2026, 4:00 PM EST
0.84 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
0.7534 Day range 0.85
0.75 52-week range 1.88
- YTD
- -20.01%
- 1 year
- -46.16%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.
benzinga.com Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) -…- benzinga.com Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio's global intellectual property portfolio in the…
benzinga.com Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…- benzinga.com Phio Pharmaceuticals Commences Manufacturing The First Commercial-scale Batch Of PH-762 Drug Substance At Nitto Denko Avecia Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in June 2025. Under the agreement to date, Avecia has successfully concluded a series of important…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.23) by 47.83 percent. This is a 27.66 percent increase over losses of…
benzinga.com Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
benzinga.com Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy for cutaneous carcinomas. In its Phase 1b trial, Phio has reported that 22 patients…- benzinga.com Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Carcinomas, To Be Presented March 28th The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating Dose Study of INTASYL PH-762 for Cutaneous Carcinomas", will highlight results of Phio's Phase 1b…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday? Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% response rate. Analysts maintain Buy ratings as shares trade near 52-week lows.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its PH-762 skin cancer drug, with FDA talks planned in 2026.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be Pathologic Responders, Including 10 With 100% Clearance Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
- benzinga.com Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin In Q1 2026 Following Phase 1b Skin Cancer Results Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO)…
- benzinga.com Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
- benzinga.com Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.40) by 10 percent. This is a 71.43 percent increase over losses of $(1.54)…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05 Pricing On 4.65M Shares Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today…
benzinga.com Why Is Phio Pharmaceuticals Stock Soaring Today? Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
benzinga.com Phio Pharma To Present Update On Proprietary INTASYL siRNA Technology And Progress On On-Going Clinical Trial With Lead Compound PH-762 For Treatment Of Skin Cancers Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
benzinga.com Phio Pharma To Present PH-762 INTASYL siRNA Skin Cancer Trial Progress And Strategic Outlook At Life Sciences Future Conference Sept. 25-26, 2025 Key updates to include advances made in the on-going clinical trial for INTASYL siRNA lead product candidate PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio…
benzinga.com Phio Pharmaceuticals to Discuss Strategy for PH-762 Skin Cancer Drug at Investor Conference Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio…- benzinga.com Phio Pharmaceuticals Has Been Issued Canadian Patent Number 3027780 Titled "REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS" https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3027780/summary.html
- benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
- benzinga.com Phio Pharma Q2 EPS $(0.45) Misses $(0.36) Estimate Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.36) by 25 percent. This is a 87.57 percent increase over losses of $(3.62)…
- benzinga.com Phio Pharmaceuticals Announces $2.5M In Gross Proceeds From Exercise Of 928,596 Warrants At $2.00 And $2.485 Per Share And Issues 1,857,192 New Unregistered Warrants At $2.485 Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Phio Pharmaceuticals Reports Complete Tumor Clearance In cSCC Patient And Partial Response In Stage 4 Merkel Cell Carcinoma In Ongoing PH-762 Phase 1b Trial Complete Pathologic Response in patient with cutaneous squamous cell carcinomaPartial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025)…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Phio Pharma (NASDAQ:PHIO) with a Buy and maintains $14 price target.
- benzinga.com 1. Phio Pharma CEO To Present New Skin Cancer Data On Groundbreaking Gene-Silencing Therapy PH-762 Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com HC Wainwright & Co. Assumes Phio Pharma at Buy, Announces Price Target of $14 HC Wainwright & Co. analyst Joseph Pantginis assumes Phio Pharma (NASDAQ:PHIO) with a Buy rating and announces Price Target of $14.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session